5 not yet recruiting, 2 terminated, 1 active not recruiting, 1 recruiting. 9 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Not yet recruiting 5, Terminated 2, Active not recruiting 1, Recruiting 1 |
| Phase 2 | 5 | Not yet recruiting 3, Recruiting 1, Terminated 1 |
Follow B Cell Malignancies: new trials by email Literature Review of B Cell Malignancies trials Research Report on B Cell Malignancies
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| CD19/70 Bi-specific CAR-T Cell Therapy bi-4SCAR CD19/70 T cells - B Cell Malignancies | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-01 | 2026-08-26 |
| CD19/22 Bi-specific CAR-T Cell Therapy bi-4SCAR CD19/22 T cells - B Cell Malignancies | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 60 | 2027-06-01 | 2026-08-26 |
| 4SCAR19U T Cells Targeting B Cell Malignancies Universal CD19-specific CAR gene-engineered T cells - B Cell Malignancies | Phase 1 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2026-12-31 | 2026-09-01 |
| A Phase 1/2 Study of T-cell Expressing a Novel CD19 Chimeric-Antigen Receptor (SHB-02-CD19) in Patients With CD19-expressing B-cell Malignancies SHB-02-CD19 (anti CD19 CAR-T cells) - B Cell Malignancies, Acute Lymphobkastic Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Sheba Medical Center | 50 | 2026-06-01 | 2026-03-31 |
| CD19/79b Bi-specific CAR-T Cell Therapy bi-4SCAR CD19/79b T cells - B Cell Malignancies | Phase 1 / Phase 2 | Terminated | Shenzhen Geno-Immune Medical Institute | 60 | 2026-06-01 | 2026-08-24 |
| Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial) Experimental Intervention - B Cell Malignancies, B-cell Leukemia | Phase 1 | Not yet recruiting | University Hospital, Basel, Switzerland | 12 | 2026-06-01 | 2025-12-24 |
| A Phase 1/2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expressing B-cell Malignancies CD22 CAR-T cells - B Cell Malignancies | Phase 1 / Phase 2 | Recruiting | Sheba Medical Center | 50 | 2026-02-01 | 2026-01-16 |
| Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets ABBV-525 - Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Active not recruiting | AbbVie | 78 | 2023-04-04 | 2026-05-04 |
| A Phase I Study of WT1 Peptides to Induce Anti-Leukemia Immune Responses Following Transplantation WT1 derived peptides - Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia (CML) | Phase 1 | Terminated | Michael Morse, MD | 8 | 2007-06-01 | 2013-12-10 |
Lymphoma, Non-Hodgkin (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Cytokine Release Syndrome (1) · Leukemia (1) · Leukemia, B-Cell (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Acute (1) · Lymphoma (1) · Lymphoma, B-Cell (1) · Lymphoma, Large B-Cell, Diffuse (1) · Myelodysplastic Syndromes (1) · Neoplasms (1) · Recurrence (1)
Hematologic Diseases (4) · Hemic and Lymphatic Diseases (4) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Lymphatic Diseases (4) · Lymphoproliferative Disorders (4) · Neoplasms by Histologic Type (4) · Disease Attributes (3) · Leukemia (3) · Leukemia, Lymphoid (3) · Neoplasms (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3) · Chronic Disease (2) · Lymphoma (2)
Shenzhen Geno-Immune Medical Institute (4) · Sheba Medical Center (2) · AbbVie (1) · Michael Morse, MD (1) · University Hospital, Basel, Switzerland (1)
China (4) · Israel (3) · United States (2) · Australia (1) · Belgium (1) · France (1) · Germany (1) · South Korea (1) · Spain (1) · Switzerland (1) · Taiwan (1) · United Kingdom (1)
Amy Hobeika, PhD (1) · Andreas Holbro, Prof. Dr. (1) · Michael A Morse, MD (1) · Nelson Chao, MD (1) · Prof. Elad Jacoby, MD (1)
2025 (1)